Recent studies indicated that CXCL5 is aberrantly expressed in >14 different types of cancer, including hepatocellular carcinoma, prostate cancer, pancreatic cancer, and gastric cancer [17]. This evidence concerns the gene CXCL5 and hepatocellular carcinoma.